HC Wainwright Boosts Earnings Estimates for Krystal Biotech

Key Points

• HC Wainwright raised its FY2026 earnings estimate for Krystal Biotech to $7.71 per share from $7.10, above the current consensus estimate of $7.33. The firm maintained a Buy rating and a $361 price target.
• Krystal reported quarterly EPS of $2.05, beating the $1.79 consensus, while revenue of $127.34 million also exceeded expectations.
• Analyst sentiment is broadly positive: MarketBeat reports a Moderate Buy consensus rating and an average price target of $375.

Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) - Analysts at HC Wainwright upped their FY2026 earnings estimates for shares of Krystal Biotech in a research note issued to investors on Monday, November 2nd. HC Wainwright analyst J. Pantginis now forecasts that the company will earn $7.71 per share for the year, up from their prior estimate of $7.10. HC Wainwright has a "Buy" rating and a $361.00 price target on the stock. The consensus estimate for Krystal Biotech's current full-year earnings is $7.33 per share. HC Wainwright also issued estimates for Krystal Biotech's Q4 2026 earnings at $2.04 EPS, FY2027 earnings at $7.50 EPS and FY2028 earnings at $12.82 EPS.

A number of other equities analysts also recently weighed in on KRYS. Bank of America boosted their target price on shares of Krystal Biotech from $392.00 to $400.00 and gave the stock a "buy" rating in a report on Monday, September 21st. William Blair upgraded shares of Krystal Biotech to a "strong-buy" rating in a research note on Wednesday, September 23rd. Jefferies Financial Group reissued a "buy" rating and issued a $474.00 price objective on shares of Krystal Biotech in a research report on Monday, July 13th. Weiss Ratings upgraded shares of Krystal Biotech from a "buy (b-)" rating to a "buy (b)" rating in a research note on Friday, October 23rd. Finally, Citigroup dropped their target price on shares of Krystal Biotech from $416.00 to $412.00 and set a "buy" rating on the stock in a report on Tuesday. Two research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $375.00.

Krystal Biotech Price Performance

Krystal Biotech stock opened at $305.03 on Wednesday. The firm has a 50-day moving average of $335.72 and a 200-day moving average of $308.77. Krystal Biotech has a one year low of $192.52 and a one year high of $382.54. The company has a market cap of $9.03 billion, a price-to-earnings ratio of 41.39 and a beta of 0.56.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its quarterly earnings data on Monday, November 2nd. The company reported $2.05 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.79 by $0.26. Krystal Biotech had a return on equity of 17.02% and a net margin of 47.91%. The business had revenue of $127.34 million during the quarter, compared to the consensus estimate of $125.77 million.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Parallel Advisors LLC raised its stake in Krystal Biotech by 2.0% in the third quarter. Parallel Advisors LLC now owns 1,733 shares of the company's stock valued at $576,000 after purchasing an additional 34 shares in the last quarter. Signaturefd LLC lifted its position in Krystal Biotech by 27.3% during the third quarter. Signaturefd LLC now owns 168 shares of the company's stock worth $56,000 after purchasing an additional 36 shares during the period. Torray Investment Partners LLC grew its stake in Krystal Biotech by 0.4% during the first quarter. Torray Investment Partners LLC now owns 12,032 shares of the company's stock worth $3,108,000 after buying an additional 47 shares in the last quarter. Oregon Public Employees Retirement Fund grew its stake in Krystal Biotech by 0.9% during the first quarter. Oregon Public Employees Retirement Fund now owns 5,949 shares of the company's stock worth $1,537,000 after buying an additional 53 shares in the last quarter. Finally, Hanseatic Management Services Inc. increased its holdings in Krystal Biotech by 2.0% in the 3rd quarter. Hanseatic Management Services Inc. now owns 3,183 shares of the company's stock valued at $1,059,000 after buying an additional 63 shares during the period. Institutional investors and hedge funds own 86.29% of the company's stock.

Insider Buying and Selling at Krystal Biotech

In other news, Director Dino A. Rossi sold 25,000 shares of the stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $329.12, for a total value of $8,228,000.00. Following the transaction, the director directly owned 50,000 shares of the company's stock, valued at $16,456,000. This represents a 33.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Suma Krishnan sold 25,000 shares of the stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $359.32, for a total transaction of $8,983,000.00. Following the completion of the transaction, the insider directly owned 1,302,145 shares in the company, valued at $467,886,741.40. The trade was a 1.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 13.10% of the company's stock.

More Krystal Biotech News

Here are the key news stories impacting Krystal Biotech this week:

• Positive Sentiment: Third-quarter revenue rose about 30% to $127.34 million, and EPS of $2.05 topped analyst expectations. Vyjuvek’s performance helped drive the growth. Krystal Biotech Q3 Net Income Falls, Revenue Rises; Shares Up Pre-Bell
• Positive Sentiment: The company announced a $400 million share-repurchase program, which may support demand for the stock. Krystal outlines $400M share repurchase
• Neutral Sentiment: Citigroup, TD Cowen, and RBC trimmed their price targets but retained Buy or Outperform ratings, signaling continued optimism alongside more cautious valuation assumptions. RBC on Krystal Biotech prospects
• Negative Sentiment: Net income declined from a year earlier, and several pipeline timelines have slipped into 2027. Those factors appear to have weighed on shares despite the earnings beat and revenue growth. Krystal beats on Vyjuvek strength, but pipeline timelines slip

About Krystal Biotech

Krystal Biotech, Inc is a biotechnology company focused on developing and commercializing genetic medicines for rare diseases. The company's platform uses modified herpes simplex virus type 1 vectors to deliver functional genes to target tissues, with an emphasis on therapies that can be administered repeatedly.

Krystal's lead product, VYJUVEK, is a topical gene therapy for wounds associated with dystrophic epidermolysis bullosa, a rare inherited skin disorder caused by mutations affecting type VII collagen.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.